- Home
- LNZA vs INMB Comparison
LNZA vs INMB Comparison
Compare LNZA & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNZA | INMB |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.5M | 64.7M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LNZA | INMB |
|---|---|---|
| Price | $6.05 | $1.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 46.8K | ★ 313.1K |
| Earning Date | 11-18-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ 17.00 | N/A |
| Revenue | ★ $55,845,000.00 | $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.36 | ★ N/A |
| Revenue Growth | 12.61 | ★ 257.14 |
| 52 Week Low | $5.02 | $1.09 |
| 52 Week High | $44.00 | $2.60 |
Technical Indicators
Market Signals| Indicator | LNZA | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 53.81 | 37.87 |
| Support Level | $5.53 | $1.36 |
| Resistance Level | $6.45 | $2.46 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 71.41 | 11.30 |
Price Performance
Historical ComparisonAbout LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a provider of carbon management and conversion technologies, focused on transforming waste materials into high-value fuels, chemicals, and critical industrial inputs. Its mission is to drive energy resilience, industrial competitiveness, and supply chain security by leveraging scalable biotechnology solutions to maximize the value of domestic resources. The company operates in North America, Europe, the Middle East, Africa (EMEA), Asia, and Australia, with the majority of its revenue generated from North America.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.